Acute promyelocytic leukemia (AML-M3) is the best-treated acute leukemia, and most cured patients do not relapse and have long-term survival. Very few high-risk patients have shortened survival after relapse. Acute promyelocytic leukemia is a special type of acute myeloid leukemia (AML). In the past three decades, due to the standardized clinical application of all-trans retinoic acid (ATRA) and arsenic (arsenic trioxide), AML has become a leukemia that can be cured basically without hematopoietic stem cell transplantation. During initial treatment, patients are categorized as low risk, intermediate risk, or high risk according to their peripheral blood leukocyte counts, and then different induction and consolidation and maintenance regimens are chosen. Most patients can be clinically cured without relapse, and will survive for a long period of time until their natural lifespan. A very small number of high-risk patients may experience relapse, and survival varies according to whether they can achieve remission after treatment. Since the overall survival situation is good, it is fortunate to have M3. After the disease is in remission, patients should maintain a comfortable and calm mood, eat regularly and exercise, and follow the doctor’s instructions for regular checkups in order to improve the quality of life. The use of medication needs to be under the guidance of a physician.